
		Site Map

For many patients, seeing their cancer return again can be more frightening than the original diagnosis. But the battle is far from over because there are many treatment options to explore. Hycamtin has a proven ability to make “second-line” treatment of ovarian and small cell lung cancer more effective. Hycamtin/cisplatin has a proven ability to increase survival versus cisplatin alone for stage IV-B, recurrent, and persistent cervical cancer.

Health care professionals, please click here.

To learn more about your cancer and how Hycamtin
may be able to help, click on a health topic below.
Ovarian Cancer Small Cell Lung Cancer Cervical Cancer

Remember, no one source can answer all your questions or replace the information provided by your doctors and nurses. This Web site is not intended to replace regular communication between you and your health care team.

Important Safety Information

Use of Hycamtin

Hycamtin is used for the treatment of recurrent ovarian cancer.

Hycamtin is used for the treatment of small cell lung cancer that returns at least 2 months after completion of your first treatment.

Hycamtin plus cisplatin is used for the treatment of cervical cancer, if it is widespread when first diagnosed, doesn’t go away with your first series of treatments, or comes back in a form that can’t be cured with surgery or radiation.

Reasons Not to Use Hycamtin

Do not use if you have had an allergic reaction to Hycamtin, if you are pregnant, if you are breast-feeding, or if you have low blood counts.

Side Effects

Hycamtin can interfere with your body’s ability to make white and red blood cells. Your doctor may prescribe a supportive therapy to help your body make more blood cells.

Side effects often associated with Hycamtin when used alone included nausea (64%), vomiting (45%), diarrhea (32%), hair loss (49%), fatigue (29%), and shortness of breath (22%). Most of these side effects were mild to moderate.

Side effects often associated with Hycamtin plus cisplatin when used to treat cervical cancer included low blood counts, pain (22%), vomiting (15%), nausea (14%), other digestive problems (14%), abnormal laboratory tests that may or may not cause symptoms (14%), and bladder/pelvic problems (12%).

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Complete Prescribing Information is provided in Adobe’s Portable Document Format (PDF).
To view this file, you will need to have the Adobe® Acrobat® Reader™ plug-in installed in your
browser. If you do not have the Acrobat Reader, follow the link to the left to download a copy.